DF/HCC Program Affiliation

DF/HCC Associations

Research Abstract

Publications

• McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.Double-blind randomized phase II study of the combi
  18445842
• Ernstoff M, Regan MM, McDermott DF, Sosman JA, Dutcher JP, Clark JI, Crocenzi TS, Ochoa A, Atkins MB.First Line therapy with bevacizumab (B) and high dose bolus (HD) aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) Patients (Pts).The Cytokine
• Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D.Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic
  17876014
• McDermott DF.Update on the application of interleukin-2 in the treatment of renal cell carcinoma.Clin Cancer Res 2007 Jan 15;13(2):716s-20s.
  17255299
• McDermott DF, Sosman J, Kirkwood J, Logan T, Gordon M, Flaherty L, Clark J, Weiss G, Margolin K, Ernstoff M, Urba W, Smith J, Parker R, Dutcher J, Atkins, M.A Randomized Phase II Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Inter
• Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB.Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy.J Immunother 2005 Sep-Oct;28(5):488-95.
  16113605
• Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S.Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.Clin Cancer Res 2005 May 15;11(10):3714-21.
  15897568
• Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC.Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.Cancer Res 20
  15833831
• McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.Randomized phase III trial of high-dose interleukin-2
  15625368
• McDermott DF, Atkins MB.Application of IL-2 and other cytokines in renal cancer.Expert Opin Biol Ther 2004 Apr;4(4):455-68.
  15102596
• McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
  10873069
• McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB.A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.Clin Cancer Res 1998 May
  9607578